-
-
-
-
-
-
-
-
- ● Diet-Induced Obesity (DIO) Mouse Model
- ● Type 1 Diabetes Mellitus (T1DM) Mouse Model
- ● Type 2 Diabetes Mellitus (T2DM) Mouse Model
- ● Diet-induced Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Mouse Model
- ● Chemically Induced Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Mouse Model
- ● Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Mouse Model (Gene-editing)
- ● Composite (Combined) Model - Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Model
- ● Composite Model - Atherosclerosis Mouse Model
- ● Atherosclerosis Mouse Model (Gene-editing)
- ● Acute Pancreatitis Mouse Model
- ● Chronic Pancreatitis Mouse Model
-
-
-
-
-
-
-
-
-
> more
In Vitro Efficacy Evaluation
In vitro drug efficacy evaluation is an important step in drug screening, and the main indicators for evaluating the efficacy of cell therapy drugs such as CAR-T and CAR-NK usually include cell killing activity, killing specificity, cell proliferation ability, and cytokine secretion ability, among others. Cyagen has rich experience in cell drug efficacy evaluation and can meet your diverse testing requirements.
Service Offering
- CAR-T/NK cell proliferation
- CAR-T/NK cell cytotoxicity
- CAR-macrophage phagocytosis assay
- Cytokine detection
- Antibody drug ADCC and ADCP
Deliverables：Experimental report
Customer-provided materials：CAR-T/NK cells (optional), target cells (optional), experimental samples, such as cell culture supernatant, animal serum, etc., and experimental design requirements.
Why choose Cyagen?
- Extensive experience in experimental design
- Diverse experimental methods
Case Study
-
In Vitro Efficacy Evaluation of CD19 CAR-T Cell
Figure 1. Experimental detection of CD19 CAR-T cell in vitro pharmacological evaluation.
A. CD19 CAR molecular structure diagram;
B. CD19 CAR-T cell positivity detection results;
C. Nalm6 cell CD19 antigen positivity detection results;
D. Statistical results of CD19 CAR-T cell killing of Nalm6 cells, showing significant enhanced killing effect of CD19 CAR-T cells on Nalm6 cells.
E. Detection results of IFN-γ in the supernatant of the killing assay, showing significantly increased secretion of IFN-γ by CD19 CAR-T cells co-cultured with Nalm6 cells.
-
In Vitro Efficacy Evaluation of GPC3 CAR-NK Cell
Figure 2. Results of in vitro efficacy assessment of GPC3 CAR-NK cells.
A. Schematic diagram of GPC3 CAR molecule structure.
B. Detection results of GPC3 CAR-NK cell positivity rate.
C. Detection results of GPC3 antigen positivity rate on HepG2 and Huh7 cells.
D. Detection results of IFN-γ in the supernatant of GPC3 CAR-NK cells co-cultured with HepG2 cells, showing significant enhancement of IFN-γ secretion ability of GPC3 CAR-NK cells compared to HepG2 cells.
E. Detection results of IFN-γ in the supernatant of GPC3 CAR-NK cells co-cultured with Huh7 cells, showing significant enhancement of IFN-γ secretion ability of GPC3 CAR-NK cells compared to Huh7 cells.
-
In Vitro Efficacy Evaluation of GPC3 UCAR-T Cells
Figure 3. Results of in vitro efficacy evaluation of GPC3 UCAR-T cells.
A. Detection results of GPC3 CAR-T and GPC3 UCAR-T cell positivity rate.
B. Imaging results of GPC3 CAR-T and GPC3 UCAR-T cell killing of EGFP-Huh7 cells under a fluorescence microscope, showing that both types of cells can effectively eliminate tumor cells.
C. Flow cytometry results of GPC3 CAR-T and GPC3 UCAR-T cell killing of EGFP-Huh7 cells, with EGFP-positive cells representing residual tumor cells, showing that both types of cells can effectively eliminate tumor cells.
D. Statistical results of the flow cytometry data in C, showing that compared to T cells, GPC3 CAR-T and GPC3 UCAR-T cells can effectively kill Huh7 cells, and there is no significant difference between the two.
E. Detection results of IFN-γ in the supernatant of the killing assay, showing that compared to T cells, both GPC3 CAR-T and GPC3 UCAR-T cells have significantly increased IFN-γ secretion ability when co-cultured with Huh7 cells, and there is no significant difference between the two.
